| CAS NO: | 957-56-2 |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| Cas No. | 957-56-2 |
| 别名 | 氟茚二酮 |
| Canonical SMILES | O=C1C2=C(C(C1C3=CC=C(C=C3)F)=O)C=CC=C2 |
| 分子式 | C15H9FO2 |
| 分子量 | 240.2 |
| 溶解度 | DMF: insol,DMSO: 1 mg/ml,Ethanol: 1 mg/ml,PBS (pH 7.2): insol |
| 储存条件 | -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Fluindione is a vitamin K antagonist.1It inhibits vitamin K epoxide reductase (VKOR; IC50= 6.6 nM), including VKOR containing certain substitution mutations. Fluindione inhibits platelet and fibrin deposition, as well as prevents β-thromboglobulin release and thrombin-antithrombin complex formation, in anex vivomodel of tissue factor-induced thrombus formation using isolated human whole blood.2Fluindione has previously been used in the treatment of emboligenic heart disease, deep vein thrombosis, pulmonary embolism, and in the prevention of thromboembolic complications in patients with heart disease. 1.Chen, X., Jin, D.-Y., Stafford, D.W., et al.Evaluation of oral anticoagulants with vitamin K epoxide reductase in its native milieuBlood132(18)1974-1984(2018) 2.Bossavy, J.P., Sakariassen, K.S., Thalamas, C., et al.Antithrombotic efficacy of the vitamin K antagonist fluindione in a human ex vivo model of arterial thrombosis: Effect of anticoagulation level and combination therapy with aspirinArterioscler. Thromb. Vasc. Biol.19(9)2269-2275(1999) |
m.cnreagent.com